Platelet-Derived Interleukin-1 Induces Cytokine Production, but not Proliferation of Human Vascular Smooth Muscle Cells

Abstract

During vascular injury, such as observed in atherosclerosis, restenosis, vasculitides, transplantation, or sepsis, vascular smooth muscle cells (SMC) can be exposed to platelets or platelet products. Under these conditions proliferation or cytokine production of SMC stimulated by platelets or platelet products may contribute to regulation of vascular pathogenesis. Thus, we investigated interleukin-6 (IL-6) and IL-8 production as well as proliferation of SMC in response to platelets or platelet lysates. Platelets not already preactivated by thrombin induced IL-6 (10- to 50-fold) or IL-8 production of unstimulated SMC in a cell number dependent fashion. Preactivation of platelets with thrombin potently increased the platelet-mediated IL-6 (50- to 1,000-fold) and IL-8 production of SMC. Hirudin specifically inhibited the activation of platelets with thrombin. Isolated platelets cultured in the absence of SMC did not contain detectable IL-6 or IL-8. Prestimulation (4 hours) of SMC with pathophysiologically relevant substances (lipopolysaccharide [LPS], tumor necrosis factor-α [TNF-α], or IL-1α) further increased the platelet-induced cytokine production. The platelet-derived SMC stimulatory activity was IL-1, since IL-1 receptor antagonist (IL-1-Ra) inhibited the platelet-induced cytokine production of SMC. Anti-platelet-derived growth factor (PDGF)-antibody did not further reduce this activity. Thrombin itself stimulated expression of IL-6 and IL-8 to some degree and induced IL-6 production of SMC synergistically with IL-1. Platelets also induced proliferation of SMC, however, anti-PDGF antibodies, rather than IL-1-Ra blocked this response. These data show that platelet-derived IL-1 stimulates cytokine production of vascular smooth muscle cells, indicating that platelet-derived IL-1 may contribute to regulation of local pathogenesis in the vessel wall by activation of the cytokine regulatory network.

Platelets Induce Thymic Stromal Lymphopoietin Production by Endothelial Cells: Contribution to Fibrosis in Human Systemic Sclerosis

“…Activated platelets promote the secretion of TSLP by ECs via an IL-1b-and serotonin-dependent mechanism. Among the IL-1b-secreting cells activated in SSc patients, platelets were of significant interest (10,24).…”

Ticagrelor Inhibits Toll-Like and Protease-Activated Receptor Mediated Platelet Activation in Acute Coronary Syndromes

“…While aspirin alone did not affect platelet surface expression of P-selectin and activated GPIIb/ IIIa in response to Pam3CSK4 and LPS, concomitant therapy with ticagrelor resulted in a modest inhibition of TLR-mediated platelet activation [60]. Furthermore, several studies found TLR and PAR signaling to be involved in the splicing of mRNA encoding for the inflammatory cytokine IL-1ß in platelets [61][62][63]. The observation by Jiang et al that patients on ticagrelor therapy had significantly lower IL-1ß levels than clopidogrel-treated patients 1 year post ACS may therefore point towards inhibition of TLR and PAR mediated platelet activation by ticagrelor [64].…”

Platelet lysate for COVID-19 pneumonia—a newer adjunctive therapeutic avenue

“…Platelets possess antimicrobial (via antimicrobial peptides) and phagocytic activity which is possible because of the cross-talks with a wide range of microbial spectra (13,14) and possesses pro-inflammatory cytokines (IL-1α) which modulate inflammatory and immune responses (15). Platelets execute the innate immune mechanism due to the expression of toll-like receptors (TLRs), such as TLR-2, -4, and -9 which is the basis for platelet-neutrophil interactions and it results in extracellular entrapment that kills the bacteria (16).…”